Advertisement
Collaboration › Details
Biodesix–MRM Proteomics: MALDI-TOF mass spectrometry, 201901– collab use of iMALDI technologies to advance blood-based lung cancer test
Period | 2019-01-28 | |
Partner, 1st | Biodesix Inc. | |
Partner, 2nd | MRM Proteomics Inc. | |
Product | iMALDI technology (immunoMALDI technology) | |
Product 2 | clinical mass spectrometry-based proteomic test | |
MRM Proteomics Inc.. (1/28/19). "Press Release: MRM Proteomics and Biodesix Partner to Develop Precision Lung Cancer Diagnostics". Montréal, QC & Boulder, CO.
Deal Underscores Need for Proteomic Data to Enable Precision Medicine
MRM Proteomics Inc. and Biodesix® have inked a partnership to create novel assays to answer critical clinical questions within the lung cancer continuum of care. Under terms of the deal, MRM Proteomics will grant Biodesix rights to utilize its proprietary iMALDI technologies to further advance its blood-based lung cancer diagnostics. Both companies share a commitment to advancing precision medicine’s accuracy and accessibility to cancer patients.
“Examining a patient’s genomic data has advanced targeted therapies. However, proteins are the targets of most drugs and hold the key to unlocking the promise of precision medicine,” said Christoph Borchers, CSO for MRM Proteomics. “Biodesix is a natural partner for our proteomic technology, because they are committed to a multi-omics approach to reveal a more complete molecular profile of lung cancer in the body. We believe that this partnership will produce much-needed advances in the proteomic space and lead to more precise lung cancer diagnostic tools that can help guide treatment decisions.”
Lung cancer is a leading cause of cancer deaths worldwide. The ability to diagnose cancer at an early stage can improve overall survival rates; the ability to rule out cancer for those at risk can reduce patient anxiety and unnecessary procedures. Precision diagnostic tools are needed to give patients and clinicians accurate, timely information. The MRM Proteomics / Biodesix partnership underscores the role of proteomics in delivering these tools.
“Elevating the importance of proteomics in revealing the full complexity of cancer is critical to getting patients the right treatment at the right time. MRM Proteomics is a leader in providing technologies that can help us unleash this potential,” said Scott Hutton, COO for Biodesix.
Learn how proteomic profiling reveals the real-time complexity of disease and the immune response by visiting here.
About Biodesix
Biodesix is a lung cancer diagnostic company addressing the continuum of patient care from early diagnosis of lung nodules through late stage cancer. The company develops diagnostic tests addressing important clinical questions by combining simple blood draws and multi-omics with the power of artificial intelligence. Biodesix is the first company to offer three best-in class tests for patients with non-small cell lung cancer, and multiple pipeline tests including one with the potential to identify patients who may benefit from immunotherapies. The Biodesix Lung Reflex strategy integrates the GeneStrat® and VeriStrat® tests to support treatment decisions with results in 72 hours. The BDX-XL2 nodule test evaluates the risk of malignancy, enabling physicians to triage patients to the most appropriate course of action. Biodesix also partners with the world’s leading biotechnology and pharmaceutical companies to develop companion diagnostics. For more information about Biodesix, please visit www.biodesix.com.
About MRM Proteomics Inc.
MRM Proteomics Inc. (MRM Proteomics) is a Canadian biotechnology company, founded in 2010 to commercialize cutting-edge proteomics technologies. MRM Proteomics operates as a CRO and research partner for clients in biotechnology and pharmaceutical industries. The company’s mission is to deliver the highest quality of precision proteomics technologies in the form of products, services, and clinical diagnostic development. As experts in mass spectrometry, their technology portfolio includes protein quantitation, protein and biosimilar structural characterization, tissue imaging, phosphoproteomics and metabolomics as well as custom-tailored solutions. MRM Proteomics also offers PeptiQuantTM Plus and MetaboloMetricsTM kits for mass spectrometry-based quantitation of proteins and metabolites.
Contacts
Media Contacts:
Kena Hudson for Biodesix
Kena@HudBio.com
(510) 908-0966
Constance Sobsey for MRM Proteomics Inc.
sobsey@mrmproteomics.com
(514) 886-2034
Record changed: 2019-03-14 |
Advertisement
More documents for Biodesix Inc.
- [1] Oncimmune Holdings plc. (6/28/19). "Press Release: Oncimmune Secures Strategic Commercialisation Agreement for EarlyCDT Lung in the US with Biodesix, Inc.". London....
- [2] MRM Proteomics Inc.. (1/28/19). "Press Release: MRM Proteomics and Biodesix Partner to Develop Precision Lung Cancer Diagnostics". Montréal, QC & Boulder, CO....
- [3] Biodesix, Inc.. (7/9/18). "Press Release: Biodesix Extends Lung Franchise with Acquisition of Integrated Diagnostics". Boulder, CO....
- [4] Biodesix, Inc.. (4/30/18). "Press Release: New Data Demonstrate the Biodesix VeriStrat Liquid Biopsy Test Reliably Informs Lung Cancer Treatment Decisions". Boulder, CO....
- [5] Biodesix, Inc.. (3/20/18). "Press Release: Biodesix Announces Biomarker Research Collaboration with Checkmate Pharmaceuticals"....
- [6] Biodesix, Inc.. (3/5/18). "Press Release: Biodesix Raises Add-On to Series G, Enters into Debt Refinancing Agreement with Innovatus Capital Partners, Scott Hutton Joins Biodesix". Boulder, CO....
- [7] Biodesix, Inc.. (5/22/17). "Press Release: New Study Shows Advanced Diagnostic Tests, Including the VeriStrat Test, Can Help Physicians Improve Cancer Care Planning and Reach Quality Measures For Patients"....
- [8] Biodesix, Inc.. (4/5/17). "Press Release: Biodesix Presents Data from Three Studies at AACR Annual Meeting". Boulder, CO....
- [9] Biodesix, Inc.. (3/20/17). "Press Release: Study Results from Biodesix’s Immunotherapy Test Will Be Presented by Dr. Jeffrey Weber. Proteomic Test Identifies Sensitivity and Resistance to Immunotherapy in Cancer Patients"....
- [10] Biodesix, Inc.. (3/9/17). "Press Release: Biodesix and Progenetics Announce Distribution Agreement for Israel". Boulder, CO....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top